Rick Silva

Executive Director of Clinical Trials, Institute of Biosciences and Technology, Texas A&M University

Appears in 1 story

Stories

FDA clears personalized magnetic brain therapy for PTSD after trial reports high remission

Described the trial design and regulatory path in the university's release

The Food and Drug Administration cleared a personalized magnetic brain therapy for PTSD in June 2026. The maker's trial reports a 68% remission rate, more than four times the maximum seen in a 2020 review of standard PTSD medications.

Updated 3 hours ago